Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308367 | 1.00 | GABRP (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12377749 | 0.87 | TSHR (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1671635 | 0.87 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11918241 | 0.87 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2622481 | 0.87 | TSHR (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24256293 | 0.85 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24725437 | 0.85 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4474378 | 0.83 | — | — | |
| SCHEMBL9860318 | 0.83 | — | — | |
| SCHEMBL9860320 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776982-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170081303-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20160368889-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | CORSAIR PHARMA INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-9505737-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160326307-A1 | POLYESTER HYDROGELS | BASF SE (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9371264-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| WO-2016010538-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150166503-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. | 2015-06-18 | — | — | US | disclosed |
| US-20140256730-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014110491-A1 | PRODRUGS OF TREPROSTINIL | THERATROPHIX LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | GABRP 28/4885GABRD 53/4885GABRA1 159/4885 |
| US-20150166503-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | GABRP 1595/4885GABRD 2296/4885GABRA1 3563/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | GABRP 622/4885GABRD 1528/4885GABRA1 1125/4885 |
| US-20170081303-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | GABRP 1595/4885GABRD 2296/4885GABRA1 3563/4885 |
| US-20160368889-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | GABRP 1595/4885GABRD 2296/4885GABRA1 3563/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | GABRP 770/4885GABRD 657/4885GABRA1 859/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | GABRP 770/4885GABRD 657/4885GABRA1 859/4885 |
| US-20140256730-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | GABRP 1595/4885GABRD 2296/4885GABRA1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.